Showing posts with label Cancer. Show all posts
Showing posts with label Cancer. Show all posts

Thursday, October 20, 2011

PEDIATRIC CANCER: Where are the drugs? Childhood Cancer meet the Creating Hope Act. Adult supervision still needed.

PEDIATRIC CANCER Two weeks after Kids v Cancer Founder Nancy Goodman’s eight year old son, Jacob, was diagnosed with medulloblastoma, a rare form of pediatric brain cancer, doctors gave him a round of chemotherapy. Jacob’s tumors did not respond. Why then, didn’t Jacob’s medical team change his chemotherapy protocol? Because in the last 30 years, no new drugs have been developed to treat Jacob’s form of cancer. In fact, in the past 20 years, only one drug has been expressly developed for any form of pediatric cancer. Jacob died on January 16, 2009 when he was ten years old. http://wp.me/1cg8a
http://bit.ly/okogAG


The Creating Hope Act


The Creating Hope Act of 2011 would encourage the creation of new drugs for underserved children who suffer from serious and rare medical conditions, including life-threatening cancers, by providing a voucher to pharmaceutical companies who develop such drugs. This voucher could be used to secure expedited FDA approval for any other drug — particularly a blockbuster drug– so that that drug could be delivered to market faster. The voucher would constitute a strong, market incentive for pharmaceutical companies to develop drugs for children with serious and rare diseases, such as cancer. The Act builds on the “FDA Amendments Act of 2007,” which established a voucher for drug development for neglected tropical diseases.






Monday, December 13, 2010

NKTR Significant Efficacy in ThirdLine Treatment Metastatic Breast Cancer

"These are important new results for NKTR-102 in patients with metastatic breast cancer," said Prof. Ahmad Awada, Head of the Medical Oncology Clinic at the Institut Jules Bordet in Brussels, Belgium. "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease. This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases." ....



"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer. "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ovarian cancer and now in metastatic breast cancer. This clinical benefit we've observed in tumor settings, where a highly active topoisomerase 1 inhibitor could be extremely useful, makes us very excited about the future of NKTR-102." .....